Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kukita A, et al. Among authors: kaneko s. Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4. Biochem Biophys Res Commun. 2019. PMID: 30955858
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kojima M, et al. Among authors: kaneko s. BMC Cancer. 2019 May 15;19(1):455. doi: 10.1186/s12885-019-5638-9. BMC Cancer. 2019. PMID: 31092221 Free PMC article.
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Kawata A, Honjoh H, Kawata Y, Kashiyama T, Sato M, Taguchi A, Miyamoto Y, Tanikawa M, Tsuruga T, Nagasaka K, Wada-Hiraike O, Osuga Y, Fujii T. Kojima M, et al. Among authors: kaneko s. Oncol Lett. 2020 Nov;20(5):153. doi: 10.3892/ol.2020.12014. Epub 2020 Aug 24. Oncol Lett. 2020. PMID: 32934721 Free PMC article.
Identification of the mutation signature of the cancer genome caused by irradiation.
Kageyama SI, Du J, Kaneko S, Hamamoto R, Yamaguchi S, Yamashita R, Okumura M, Motegi A, Hojo H, Nakamura M, Tsuchihara K, Akimoto T. Kageyama SI, et al. Among authors: kaneko s. Radiother Oncol. 2021 Feb;155:10-16. doi: 10.1016/j.radonc.2020.10.020. Epub 2020 Oct 17. Radiother Oncol. 2021. PMID: 33075393 Free article.
3,525 results